HCPCS J2779 is officially defined as "Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg." HCPCS J2779 is referenced in 16 tracked payer policy changes from Sentara Health Plans, Florida Blue, and 5 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J2779 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Starting January 1, 2027, Sentara Health Plans will require prior authorization for a long list of codes on Virginia commercial plans, including self-funded (ASO) plans, and for code 88380 on commercial, Medicaid and Medicare products, plus code 22860 on Medicare products. Sentara will also stop covering a separate list of codes on Virginia commercial and self-funded plans.
Florida Blue Medicare has updated its Part B Step Therapy program effective October 1, 2026, restructuring preferred and non-preferred medication classifications across six drug categories (Autoimmune Therapy, Bone Remodeling Agents, Cancer and Supportive Therapy, Colony-Stimulating Factors, Complement Inhibitors, and Ophthalmic Agents). Billing teams must verify that prescriptions align with updated preferred product lists and implement prior authorization requirements for non-preferred medications to prevent claim denials.
BlueCare Tennessee has implemented new step therapy requirements for provider-administered specialty drugs effective July 1, 2026. Providers must try preferred alternative medications before using requested specialty drugs across multiple therapeutic categories including autoimmune conditions, oncology, growth factors, and more.
Independence Blue Cross updated policy 08.00.74ab to 08.00.74ad effective 01/01/2026, adding six new VEGF antagonist biosimilars (Ahzantive, Enzeevu, Eydenzelt, Opuviz, Pavblu, Yesafili) to the preferred product list, expanding aflibercept HD coverage to include macular edema following retinal vein occlusion, adding ranibizumab (Susvimo) coverage for diabetic macular edema and diabetic retinopathy, and adding HCPCS code Q5160 for bevacizumab-nwgd biosimilar. The billing team must update systems to recognize these new biosimilars and diagnoses for proper claim processing and reimbursement.
Florida Blue Medicare updated its Part B Step Therapy programs for Medicare Advantage plans, effective January 1, 2026. Multiple drug categories now have new preferred and non-preferred medications, requiring step therapy trials of preferred products before non-preferred drugs can be approved.
Florida Blue Medicare updated its Part B Step Therapy program effective September 15, 2025, adding new non-preferred drugs to four categories that now require step therapy and prior authorization. Billing teams must ensure preferred alternatives are tried first or obtain prior authorization for the newly added non-preferred medications.
BlueCross BlueShield of Tennessee's upcoming step therapy guide for Commercial and BlueCare Plus Tennessee lists provider administered specialty drugs that need a preferred alternative tried first, including biosimilars, infused biologics, bevacizumab, botulinum toxins, hyaluronic acid injections, growth factor products and rituximab and trastuzumab products. The practice needs to check upcoming infused and injected drugs against this list and document the indication, dose, frequency and duration so requests and exceptions match the policy.
The policy update dated 11/01/2026 changes Vegzelma (bevacizumab-adcd) from non-covered to medically necessary when the listed indications are met. Alymsys (bevacizumab-maly), Beovu (brolucizumab), Cimerli (ranibizumab-eqrn), Eylea HD (aflibercept), Izervay (avacincaptad pegol), Susvimo (ranibizumab), Syfovre (pegcetacoplan) and Vabysmo (faricimab-svoa) are listed as not covered on the State Health Plan Medical Drug Formulary, and Avastin, Mvasi, Zirabev and Vegzelma are medically necessary for the listed neovascular (wet) AMD, diabetic macular edema, diabetic retinopathy, retinal vein occlusion macular edema and retinopathy of prematurity indications. Byooviz, Eylea, Lucentis and Pavblu may be considered medically necessary when the listed age, diagnosis, prior treatment and specialist criteria are met.
Vegzelma (bevacizumab-adcd) changed from non-covered to medically necessary when the listed indications are met, according to an update dated 11/01/2026. Avastin, Mvasi, Vegzelma and Zirabev are medically necessary for neovascular wet age-related macular degeneration, several other choroidal neovascularization causes, diabetic macular edema, diabetic retinopathy, macular edema after central or branch retinal vein occlusion, and retinopathy of prematurity. Byooviz, Eylea, Lucentis and Pavblu require prior authorization, while Alymsys, Beovu, Cimerli, Eylea HD, Izervay, Susvimo, Syfovre and Vabysmo are not covered on any BCBSMS Formulary.
BlueCross BlueShield of Tennessee is establishing a new medical policy effective 10/31/26 that covers five ranibizumab formulations (Lucentis, Byooviz, Cimerli, Nufymco, Ranluspec) for five FDA-approved retinal indications. The policy defines specific dosing limits by indication (0.3-0.5mg intravitreal monthly), requires ophthalmologist prescription, mandates 12-month authorizations with demonstration of positive clinical response for continuation, and references step therapy requirements. This is a NEW policy—not a revision—establishing coverage parameters for these anti-VEGF agents.
Independence Blue Cross Medicare Advantage policy MA08.073w (effective 01/01/2026) adds six new VEGF antagonist biosimilars to preferred product listings, expands coverage indications for aflibercept HD and ranibizumab Susvimo, and introduces one new HCPCS billing code (Q5160 for bevacizumab-nwgd). Billing teams must update systems to recognize these new biosimilar products and ensure correct coding for claims submitted on or after January 1, 2026.
Independence Blue Cross added HCPCS code Q5155 (aflibercept-jbvf/yesafili biosimilar, 1 mg) to policy MA08.073w effective 10/01/2025. This new aflibercept biosimilar is classified as a LEVEL 3 NONPREFERRED PRODUCT and requires prior authorization or documented failure of preferred agents (bevacizumab or ranibizumab) before coverage. Billing team must update systems to recognize this new code and apply appropriate coverage restrictions.
Aetna considers one intravitreal implant of Encelto (revakinagene taroretcel-lwey) per affected eye medically necessary for adults with idiopathic macular telangiectasia type 2 (MacTel) when the listed criteria are met, and considers all other indications experimental, investigational or unproven. The policy covers commercial medical plans, requires precertification in applicable plan designs, and requires that the drug be prescribed by or in consultation with an ophthalmologist. Members with intraretinal or subretinal neovascularization, anti-VEGF therapy within the past 3 months, glaucoma, uveitis, or current chemotherapy are listed as not eligible for the implant.
Independence Blue Cross Medicare Advantage added new HCPCS code Q5153 (aflibercept-yszy/Opuviz biosimilar) effective July 1, 2025 to their intravitreal injection policy MA08.073w. This biosimilar is classified as a Level 3 nonpreferred product under the company's tiered formulary for VEGF antagonists, meaning coverage requires prior treatment failure or contraindication to preferred products (bevacizumab Level 1, ranibizumab Level 2).
BlueCross BlueShield of Tennessee and BlueCare Plus Tennessee publish the Commercial & BlueCare PASD Step Therapy Requirements guide for provider administered specialty medications. The guide says the listed medications need step therapy, that the medication must be a provider administered specialty drug used for a medically accepted indication, and that dose, frequency and duration may not exceed the safety and efficacy data supporting that indication. The source does not state an effective date or describe what changed.
Blue Cross and Blue Shield of Louisiana added HCPCS codes A9596, A9601, C9094, C9095, C9096, C9097, J0739, J1306, J1551, J2356, J2779, J2998, J3299, J9331, J9332, Q4259, Q4260 and Q4261 to its claims system effective July 1, 2022. For dates of service on and after August 15, 2022, the COVID-19 treatment bebtelovimab is reimbursed when billed with Modifier UC, which identifies the medication as commercially purchased, and the same administration codes are used for commercially purchased and government-supplied medication. Updated professional allowable charges for flu vaccination codes take effect for dates of service on and after November 1, 2022, and the new charges can be viewed in the Professional Provider Allowable Charges Search tool in iLinkBlue. FEP requires prior authorization for admission to residential treatment centers, and an administrative denial results if prior authorization is not obtained or the member is not enrolled in New Directions care management.
Watch J2779
Get one email when a payer policy names J2779, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for J2779
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J2779 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.